Semaglutide: How the GLP-1 Peptide Revolutionized Weight Management

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has become one of the most significant breakthroughs in metabolic health research. Originally developed for type 2 diabetes, clinical trials demonstrated extraordinary weight loss results.

Mechanism of Action

Semaglutide mimics the naturally occurring GLP-1 hormone:

• •Appetite Regulation: Acts on brain receptors (particularly the hypothalamus) to reduce hunger and increase satiety
• •Insulin Secretion: Stimulates glucose-dependent insulin release from the pancreas
• •Gastric Emptying: Slows stomach emptying, prolonging the feeling of fullness
• •Glucagon Suppression: Reduces glucagon release, lowering blood sugar

Clinical Trial Results

The STEP clinical trial program showed:

• •Average weight loss of 14.9% of body weight over 68 weeks (STEP 1)
• •Significant improvements in cardiometabolic risk factors
• •Reduction in waist circumference and visceral fat
• •Improvements in blood pressure and lipid profiles

Semaglutide vs. Tirzepatide

Tirzepatide (a dual GIP/GLP-1 agonist) has shown even greater weight loss in some studies. Peptidrop's peptide database includes both peptides with side-by-side comparison data:

• •Semaglutide: Targets GLP-1 receptor only
• •Tirzepatide: Targets both GIP and GLP-1 receptors (dual agonist)

Important Considerations

Semaglutide is a prescription medication and should only be used under medical supervision. Peptidrop provides research data for educational purposes - always consult a qualified healthcare professional for medical decisions. For a broader look at weight management peptides, see our guide on the best peptides for fat loss.

For ongoing clinical trials involving Semaglutide, visit ClinicalTrials.gov. The landmark STEP trial results were published in The New England Journal of Medicine.